Management equity grant Clause Samples
Management equity grant. A quantity of options to purchase shares of the company’s common stock as agreed upon by Employee and the Company and commensurate with Employee’s role as a senior executive at the Company. The strike price for all options will be the last sale price of the Company’s common stock as reported during the period immediately preceding the date of grant and in accordance with the terms of the Company’s Stock and Incentive Plan.
Management equity grant. 200,000 total options to purchase shares of the Company’s common stock. The strike price for all options will be the last sale price of the Company’s common stock as reported on ▇▇▇▇▇▇.▇▇▇ on the Effective Date. · All options fully vest upon change in control, death, disability, termination without cause, termination for good reason · 100,000 options are fully vested on Day 1 of this agreement · 100,000 options vest 365 days thereafter
Management equity grant. ● The 1,000,000 options to purchase shares of the common stock of the Company awarded pursuant to Section 3(c) shall be granted as follows (a) 750,000 options shall be granted as of the Effective Date and (b) 250,000 options shall be granted as of January 1, 2022. ● All of the foregoing options shall fully vest upon a Change in Control, death, Disability, termination without Cause, or termination for Good Reason. ● The 750,000 options to be granted as of the Effective Date shall vest as follows: (a) 500,000 of such options shall vest on the Effective Date and (b) the remaining 250,000 options shall vest on the one-year anniversary of the Effective Date. The 250,000 options to be granted as of January 1, 2022 shall vest, in full, on the one-year anniversary of the Effective Date. ● Provide overall guidance and leadership for any licensing negotiation leading to a successfully executed transaction. ● Obtain FDA acceptance of the Biologics License Application (BLA) for Ampion. ● Obtain FDA Biologics License for Ampion for the treatment of OA for at least KL-4 patients. ● Progress the COVID-19 related clinical trials.